Related Experiment Videos
Transscleral Nd: YAG laser cyclophotocoagulation versus cyclocryotherapy
1Department of Ophthalmology, Faculty of Medicine, University of Tokyo, Japan.
Summary
Transscleral Nd: YAG laser cyclophotocoagulation (TSYLC) effectively lowers intraocular pressure (IOP) in refractory glaucoma. This glaucoma treatment shows similar efficacy to cyclocryotherapy but with a lower complication rate.
Area of Science:
- Ophthalmology
- Medical Technology
- Glaucoma Research
Background:
- Refractory glaucoma presents a significant challenge in intraocular pressure (IOP) management.
- Current treatment options for advanced glaucoma may have limitations and associated risks.
Purpose of the Study:
- To evaluate the post-operative intraocular pressure (IOP) course after transscleral Nd: YAG laser cyclophotocoagulation (TSYLC).
- To compare the efficacy and safety of TSYLC with cyclocryotherapy in refractory glaucoma patients.
Main Methods:
- Retrospective study utilizing the life-table method.
- Inclusion of 36 eyes (TSYLC) and 80 eyes (cyclocryotherapy) for first-time treatment.
- Defined success criteria based on IOP levels and visual acuity, without additional medication.
Main Results:
- TSYLC success rate at 21 months was 45.2% +/- 11.7%; cyclocryotherapy was 38.9% +/- 6.1% (not statistically significant).
- Complications including phthisis bulbi, hypotony, and anterior chamber hemorrhage were less frequent with TSYLC.
Conclusions:
- TSYLC demonstrates comparable efficacy to cyclocryotherapy in lowering IOP for refractory glaucoma.
- TSYLC offers a potentially safer alternative with a reduced incidence of complications compared to cyclocryotherapy.